Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic Mesenchymal Stem Cell Therapy in DMD
NCT02484560Phase 1Unknown
- Sponsor
- Gaziantep University
- Start
- Jun 2015
- Primary completion
- Dec 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of umbilical cord-derived allogeneic mesenchymal stem cells in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Gaziantep University. Primary endpoint: Degree of improvement in patients with Duchenne Muscular Dystrophy at 12 months. Status: unknown.
02
Drugs
umbilical cord-derived allogeneic mesenchymal stem cells
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02484560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484560.